08
2023
-
11
Shandong Yumankun Biotechnology Co., Ltd. piracetam injection ninth batch of state procurement selected
Classification:
Company News
On November 6, the ninth batch of national drug centralized volume purchasing meeting was held in Shanghai. Shandong Yumankun Biotechnology Co., Ltd. consistency evaluation over the evaluation of the product piracetam injection was selected. Piracetam is a cerebral metabolism improvement drug, belongs to the cyclic derivatives of γaminobutyric acid, has the effect of anti-physical factors, chemical factors caused by brain function damage, promote acetylcholine synthesis and enhance the conduction of neural excitation, promote the role of brain metabolism, and improve the role of retrograde amnesia caused by hypoxia, and can enhance the memory, improve the ability to learn. Piracetam Injection is suitable for acute and chronic cerebrovascular disease, traumatic brain injury, various toxic encephalopathies and other causes of memory loss and mild and moderate cerebral dysfunction. It can also be used for children with delayed intellectual development. The selection of Yumangkun Piracetam Injection means that it will be included in the national health insurance catalog, which will reduce patients' pain and economic burden and benefit the majority of patients. The national procurement selection covers 42 varieties with high social impact, and its process is strict and fair, passing through many stages of evaluation and screening to ensure the quality and efficacy of the drug. Therefore, the selection of Yumangkun Piracetam Injection is a kind of recognition of the efficacy and safety of the drug, and also a kind of affirmation to the enterprise, which is more in line with the enterprise mission of Yumangkun "focusing on pharmaceutical science and technology, and seeking health for the public". Protect the rights and interests of the majority of patients. In the future development, Yumankun will continue to "patient-centered, clinical value-oriented" as the goal, and at the same time, innovative technology path and business model, driving the transformation and upgrading of product research and development, production technology and marketing model, to innovative, international pharmaceutical group steadily marching towards China's pharmaceutical industry to make new and greater contributions to the development of the cause! The company will make new and greater contributions to the development of China's pharmaceutical industry.
Related News
2023-11-08
On November 6, the ninth batch of national drug centralized volume purchasing meeting was held in Shanghai. Shandong Yumangkun Biotechnology Co., Ltd. consistency evaluation over the evaluation of the product piracetam injection was selected.
2023-09-27
Good News｜Shandong Yumankun Biotechnology Co., Ltd. won the eighth batch of national centralized purchasing of pharmaceutical products.
2023-09-09
Circular of the National Medical Security Bureau on Further Deepening the Intelligent Audit and Monitoring of the Medical Security Fund
2023-08-30
Notice on the Filling of Information on Drugs Related to the Ninth Batch of Centralized Purchasing of Drugs by State Organizations
Address: Room 2602, Huiyuan Building, 38 Huaneng Road, Lixia District, Jinan City, Shandong Province
©Shandong Yumankun Biotechnology Co., Ltd.